Jesús G. Berdeja

18.2k total citations · 1 hit paper
257 papers, 5.0k citations indexed

About

Jesús G. Berdeja is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jesús G. Berdeja has authored 257 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 192 papers in Hematology, 136 papers in Molecular Biology and 136 papers in Oncology. Recurrent topics in Jesús G. Berdeja's work include Multiple Myeloma Research and Treatments (174 papers), Protein Degradation and Inhibitors (96 papers) and CAR-T cell therapy research (82 papers). Jesús G. Berdeja is often cited by papers focused on Multiple Myeloma Research and Treatments (174 papers), Protein Degradation and Inhibitors (96 papers) and CAR-T cell therapy research (82 papers). Jesús G. Berdeja collaborates with scholars based in United States, Spain and Canada. Jesús G. Berdeja's co-authors include David S. Siegel, Sundar Jagannath, Noopur Raje, Paul G. Richardson, Ian W. Flinn, Jonathan L. Kaufman, Yi Lin, Sagar Lonial, Amrita Krishnan and Ravi Vij and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jesús G. Berdeja

243 papers receiving 4.9k citations

Hit Papers

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antib... 2022 2026 2023 2024 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
    2022 350 citations Jesús G. Berdeja, Niels W.C.J. van de Donk et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jesús G. Berdeja United States 40 3.1k 3.0k 2.9k 717 584 257 5.0k
Bruno Paiva Spain 36 2.6k 0.9× 1.9k 0.6× 3.4k 1.2× 804 1.1× 345 0.6× 157 4.7k
Richard W.J. Groen Netherlands 28 1.3k 0.4× 1.6k 0.5× 1.5k 0.5× 830 1.2× 386 0.7× 69 3.0k
Tahamtan Ahmadi United States 27 2.1k 0.7× 2.6k 0.9× 3.1k 1.1× 938 1.3× 703 1.2× 92 4.6k
Shmuel Yaccoby United States 38 3.0k 1.0× 3.0k 1.0× 3.7k 1.3× 537 0.7× 391 0.7× 112 5.5k
Jacalyn Rosenblatt United States 31 1.5k 0.5× 1.7k 0.6× 1.3k 0.5× 1.2k 1.7× 193 0.3× 142 3.5k
Salomon Manier France 29 2.1k 0.7× 1.3k 0.4× 1.9k 0.7× 531 0.7× 228 0.4× 158 3.4k
Michael H. Tomasson United States 32 1.6k 0.5× 1.3k 0.4× 1.8k 0.6× 486 0.7× 240 0.4× 116 3.5k
María‐Belén Vídriales Spain 40 2.0k 0.7× 1.5k 0.5× 3.8k 1.3× 828 1.2× 205 0.4× 105 5.0k
Hetty E. Carraway United States 35 1.7k 0.6× 1.1k 0.4× 1.4k 0.5× 488 0.7× 130 0.2× 212 3.6k
Cyrille Touzeau France 29 1.6k 0.5× 1.5k 0.5× 1.8k 0.6× 320 0.4× 333 0.6× 204 3.0k

Countries citing papers authored by Jesús G. Berdeja

Since Specialization
Citations

This map shows the geographic impact of Jesús G. Berdeja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesús G. Berdeja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesús G. Berdeja more than expected).

Fields of papers citing papers by Jesús G. Berdeja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesús G. Berdeja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesús G. Berdeja. The network helps show where Jesús G. Berdeja may publish in the future.

Co-authorship network of co-authors of Jesús G. Berdeja

This figure shows the co-authorship network connecting the top 25 collaborators of Jesús G. Berdeja. A scholar is included among the top collaborators of Jesús G. Berdeja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesús G. Berdeja. Jesús G. Berdeja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Martin, Tom, Noopur Raje, Jesús F. San Miguel, et al.. (2024). MM-382 iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S554–S555. 1 indexed citations
3.
Berdeja, Jesús G., Min Yang, Noopur Raje, et al.. (2024). Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Carolina Digital Repository (University of North Carolina at Chapel Hill).
4.
Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2024). Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. Blood Advances. 9(2). 429–435. 4 indexed citations
5.
Lin, Yi, Thomas Martin, Saad Z. Usmani, et al.. (2023). POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226. 1 indexed citations
6.
7.
Vesole, David H., Jesús G. Berdeja, Jeffrey Matous, et al.. (2023). P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.. HemaSphere. 7(S3). e5189693–e5189693.
8.
Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S55–S55. 2 indexed citations
9.
Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2023). MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S494–S495. 1 indexed citations
10.
Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398. 2 indexed citations
11.
Raje, Noopur, Nina Shah, Sundar Jagannath, et al.. (2021). Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. Blood. 138(Supplement 1). 548–548. 66 indexed citations
12.
Vij, Ravi, Rajneesh Nath, Daniel Afar, et al.. (2020). First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research. 26(10). 2308–2317. 24 indexed citations
13.
Ghobrial, Irene M., Ravi Vij, David S. Siegel, et al.. (2019). A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clinical Cancer Research. 25(16). 4907–4916. 39 indexed citations
14.
Flinn, Ian W., Mohamad Cherry, Michael B. Maris, et al.. (2019). Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia. American Journal of Hematology. 94(12). 1325–1334. 33 indexed citations
15.
16.
Costello, Caitlin, Tara Gregory, Syed Abbas Ali, et al.. (2019). Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME). Blood. 134(Supplement_1). 3184–3184. 43 indexed citations
17.
Shah, Nina, Melissa Alsina, David S. Siegel, et al.. (2018). Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. Blood. 132(Supplement 1). 488–488. 66 indexed citations
18.
19.
Flinn, Ian W., et al.. (2017). Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. British Journal of Haematology. 180(3). 365–373. 6 indexed citations
20.
Huang, Qin, Craig W. Zuppan, Edward H. Rowsell, et al.. (2006). Hodgkin Lymphoma-Like Posttransplant Lymphoproliferative Disorder (HL-Like PTLD) Simulates Monomorphic B-Cell PTLD Both Clinically and Pathologically. The American Journal of Surgical Pathology. 30(4). 470–476. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruno Paiva Breakdown of academic impact, for papers by Richard W.J. Groen Breakdown of academic impact, for papers by Tahamtan Ahmadi Breakdown of academic impact, for papers by Shmuel Yaccoby Breakdown of academic impact, for papers by Jacalyn Rosenblatt Breakdown of academic impact, for papers by Salomon Manier Breakdown of academic impact, for papers by Michael H. Tomasson Breakdown of academic impact, for papers by María‐Belén Vídriales Breakdown of academic impact, for papers by Hetty E. Carraway Breakdown of academic impact, for papers by Cyrille Touzeau
Rankless by CCL
2026